Company Description
Apnimed is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases.
Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA).
Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
Based on results from two registrational trials, we submitted a New Drug Application (NDA) for Oxnimbi to the U.S. Food and Drug Administration (FDA) in April 2026.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jul 31, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Kevin R. Lind |
Contact Details
Address: 39 John F. Kennedy Street, 4th Floor Cambridge, MA 02138 United States | |
| Phone | (617) 500-8880 |
| Website | apnimed.com |
Stock Details
| Ticker Symbol | APMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1745648 |
| Employer ID | 82-1910611 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kevin R. Lind | Chief Executive Officer and Director |
| Michael Kelly | Chief Financial Officer |
| Dennis P. Molnar | President and Chief Operating Officer |
| John Cronin, M.D. | Chief Medical Officer |
| Graham Goodrich | Chief Commercial Officer |
| Barry Wohl | Chief Business Officer |
| Steven Spector, J.D. | Chief Legal Officer and Head of Corporate Affairs |
| Paul Sekhri | Director, Board Chair |
| Lawrence G. Miller, M.D. | Director, Vice Chair |
| Joseph Avellone, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 31, 2026 | 424B4 | Prospectus |
| Jul 30, 2026 | EFFECT | Notice of Effectiveness |
| Jul 30, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Jul 30, 2026 | CERT | Certification by an exchange approving securities for listing |
| Jul 29, 2026 | 8-A12B | Registration of securities |
| Jul 27, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 10, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 1, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Apr 22, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |